Last reviewed · How we verify
BHV-3500 (zavegepant) (bhv-3500-zavegepant)
Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms.
BHV-3500 (zavegepant), developed by Pfizer, holds a strong market position as a CGRP receptor antagonist with two approved indications and seven clinical trials completed. Its competitive advantage lies in its ability to provide rapid relief of migraine pain and associated symptoms, positioning it well against other oral and injectable CGRP antagonists like Rimegepant (Nurtec ODT) and Erenumab (Aimovig). A key risk is the intense competition from established monoclonal antibodies such as Erenumab, Fremanezumab, and Eptinezumab, which have a significant market presence and diverse dosing options. The pipeline outlook remains promising, with ongoing trials that could expand its indications and further solidify its role in the migraine treatment landscape.
At a glance
| Generic name | bhv-3500-zavegepant |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | CGRP receptor antagonist |
| Target | CGRP receptor (calcitonin gene-related peptide receptor) |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Mechanism of action
Zavegepant works by antagonizing the calcitonin gene-related peptide (CGRP) receptor, a G-protein coupled receptor found on trigeminal neurons and blood vessels. CGRP is a 37-amino acid neuropeptide released during migraine attacks and plays a central role in migraine pathophysiology by promoting neurogenic inflammation, vasodilation, and pain signal transmission. By blocking CGRP receptor binding, zavegepant interrupts this cascade, reducing the intensity and duration of migraine pain. The intranasal spray formulation allows rapid absorption through the nasal mucosa, potentially providing faster symptom relief compared to oral formulations, which is particularly valuable during acute migraine attacks when patients may experience nausea and difficulty swallowing.
Approved indications
- Acute migraine treatment — 1L
- Acute migraine treatment — 1L
Pipeline indications
- Acute migraine — Phase 3
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BHV-3500 (zavegepant) CI brief — competitive landscape report
- BHV-3500 (zavegepant) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI